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Summary An analysis has been made of the relationship between neuron specific enolase (NSE) in serum and
immunohistochemically identified occurrence of NSE in the primary tumour in 56 patients with small cell lung
cancer (SCLC). Patients were referred to the Finsen Institute for treatment during a period of 18 months.
Forty-six tumours (82%) were NSE positive. To compare this staining with the occurrence of NSE in serum, a
histological staining index (HSI) was established by semiquantitative gradation of the staining. No significant
differences were found between distribution of serum NSE values in different HSI categories, and a high
ranking in HSI was not associated with a high level of serum NSE. Both univariate and multivariate analysis
selected serum NSE and not HSI as the most influential prognostic factor in SCLC.
The gamma-gamma dimer of the enzyme neuron specific
enolase (NSE) has in small cell lung cancer (SCLC) been
isolated in tissue cultures, tumour tissue and from patients
serum (Carney et al., 1982; Gazdar et al., 1981, 1985; Maran-
gos et al., 1982; Schmechel et al., 1978). The serum level of
NSE in patients with SCLC seems to be an important prog-
nostic factor in SCLC (Akoun et al., 1985; J0rgensen et al.,
1988).
Routine classification of lung tumours is usually based on
haematoxylin and eosin staining (HE). Newer techniques as
immunohistoreactivity against tissue-enzymes and proteins
has recently been introduced with the intention to obtain
additional diagnostic information. The value of NSE
immunoreactivity in addition to conventional morphological
examination in SCLC has not yet been established.
The present study was undertaken in order to describe the
relation between serum NSE levels and the occurrence of
staining in SCLC tumour tissue and to assess the possible
prognostic value of the presence of NSE in SCLC tumour
tissue.
Materials and methods
During a period of 18 months 101 patients with SCLC were
referred to The Finsen Institute for treatment. The primary
diagnosis of SCLC was made at referral hospitals and
confirmed before initiating chemotherapy.
Eighty-six patients with a preset panel of pretreatment
blood samples were entered into a multivariate study of
prognostic factors (J0rgensen et al., 1988). Sufficient tissue
for immunostaining was available in 60 patients. Pretreat-
ment investigations enabled a classification of the disease as
limited (LD) or extensive (ED), with LD being defined as
tumour confined to one hemithorax and ipsilateral suprac-
lavicular lymph nodes.
The histologic specimens consisted of primary tumours
obtained by bronchoscopy, thoracotomy or mediastinoscopy.
All tissues were fixed in 10% formaldehyde, were embedded
in paraffin, sectioned, and stained with HE for conventional
histologic examination and classification according to WHO,
1981. From each tumour 1-2 blocks were available. From
each block 2-4 slides were selected containing sufficient
tumour tissue. The slides were then stained according to the
protocol.
For immunocytochemistry five micrometer sections were
blocked for endogenous peroxidase activity by methanol
H202 treatment for 30min. Subsequently, sections were
incubated for 1 h with a monoclonal antibody to NSE (San-
bio, Holland) diluted 1:100 in BSA/TBS (0.25% Bovine
Serum Albumin and 0.01 Molar Tris Buffer, pH = 7.4 con-
taining 0.15 Molar Sodium Chloride). The site of antigen-
antibody reaction was revealed by indirect peroxidase
method using peroxidase-labelled anti-mouse IgG (Dakopatts
A/S, Copenhagen, Denmark) as secondary antibody (1:20,
1 h). The peroxidase activity was detected by incubation in
diaminobenzidine-hydrogenperoxide medium for 10 min. For
further methodological details, see Larsson 1988. As positive
control we used a foetal human lung. The procedure was
performed by the same person carried out at the same time.
Previous studies, using the present monoclonal antibody and
type-matched IgG on similarly fixed SCLC tissue, have
demonstrated absence of unspecific staining reaction with the
monoclonal antibody to NSE (Hirsch & Larsson, unpub-
lished data). The immunostaining was assessed by one
observer (BGS) blinded for the serological results. Identical
results were achieved in repeated evaluations.
The number of stained cells in each section was scored and
categorised as follows: Neg; no staining of tumour cells.
0-10% of the tumour cells stained, 11-50% of the tumour
cells stained, and >50% of the tumour cells stained.
Differences in stain intensity was not evaluated. The
immunocytochemical evaluation was carried out 'blind' with
regard to the clinical results.
With this semiquantitative gradation of the NSE-staining,
a histological staining index (HSI) with the four groups was
established: negative, 0-10%, 11-50% and >50% stained
cells within sections.
Serum NSE was measured by a radioimmunoassay NSE-
RIA (Pharmacia Diagnostics AB, Uppsala, Sweden) (Cooper
et al., 1985). The analyses were made at Diagnostic Develop-
ment Unit, Old Medical School, Leeds.
All patients received chemotherapy according to ongoing
protocols. Survival time was counted from the first day of
treatment and differences were tested for statistical
significance by the log rank method (Peto et al., 1977).
Differences of serum NSE levels between categories of HSI
were tested by the Kruskal-Wallis one-way analysis (Kruskal,
1952) and the Mann-Whitney test (Mann & Whitney, 1947).
A significance level of P<0.05 was applied.
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Results
Classification ofimmunoreactivity
Four out of the 60 tissue specimens did not contain malig-
nant tissue and were excluded leaving 56 cases for assessment
of NSE immunoreactivity. Characteristics of these patients
are shown in Table I.
If staining was unevenly distributed, the classification was
based on the most stained area. An example of this is shown
in Figure 1. Immunoreactivity was positive in 46 tumours
(82%), distributed as 85% in LD and 77% in ED (Table II).
No significant difference was found between distribution of
HSE indices in LD and ED (Table II).
Serum NSE and immunoreactions
Serum NSE values were grouped according to HSE (Table
III). Kruskal-Wallis test of variance resulted in P = 0.90,
suggesting very similar distribution of the NSE values in the
four groups. A new test (Mann-Whitney) was therefore
carried out, comparing NSE values between categories of
negative and positive reactions respectively. Serum NSE
values within these two groups did not differ significantly.
Grouping HSI zero with 0-10% vs > 10% neither un-
covered significant differences between the serum NSE values
(Table IV).
Survival
Pretreatment level of serum NSE and extent of disease had a
significant influence on survival in univariate analysis, while
HSI did not (Table V). Exclusion of the 24 patients with
traumatised specimens still did not result in an apparent
relationship between HSI and survival. Finally, PS and
serum NSE were included in a multivariate analysis. HSI had
no significant influence while PS and NSE were important
factors (Table VI).
Table I Pretreatment characteristics in patients with SCLC
LD ED
Number 34 22
Age (median, range) 60 (41-69) 63 (38-73)
Performance 0 + 1 31 13
Status 2-4 3 9
Metastases in:
Bone marrow 11
Liver 13
Brain 3
Other 7
LD: limited disease, ED: extensive disease.
Table II NSE immunoreactivity in SCLC
Histological Staining Index
Variable Negative 0-10 11-50 >50 Total
LD (N:) 5 12 12 5 34
ED (N:) 5 4 6 7 22
Total (N:) 10 16 18 12 56
Index given as percentage stained cells in slides. LD: limited
disease, ED: extensive disease.
Table III Histologic Staining Index and serum NSE in SCLC
NSE ngml-'
Index Number Median Range
Negative 10 20.50 8.4- 86.0
0-10% 16 22.95 4.7-136.2
11-50% 18 27.15 5.7-164.1
>50% 12 25.95 8.5- 169.5
Index: percentage NSE - stained cells.
a
W.
b
Figure 1 Within identical tissue traumatised and well preserved
areas were found.
Table IV Serum NSE according to Histologic Staining Index
.1..JNl
Variables Methods P
Neg., 0-10%, 11-50%, >50% Kruskal-Wallis 0.90
Neg., Pos. Mann-Whitney 0.10
Neg+0-10% vs >,1,1% Mann-Whitney 0.10
Index: percentage NSE - stained cells.
Table V Pretreatment prognostic factors in SCLC
LTR LRT
Variable n x2 p
Extent: LD vs ED 34 22 5.520 0.025
NSE: <50.0 vs >50.0 39 17 14.510 0.0005
HSI: neg. vs pos. 10 46 3.780 0.10
HSI: <10% vs > 10% 26 30 0.270 0.70
HSI: <50% vs >50% 44 12 0.190 0.70
n: number examined, LRT: log rank test, LD: limited disease,
ED: extensive disease, HSI: histological staining index.
Table VI Results of multivariate analysis of three prognostic
factors
Regression
Variable coefficient SE P
NSE 0.4339 0.2152 <0.05
PS 0.5485 0.2100 <0.01
HSI 0.0579 0.3697 <0.80
The Cox's proportional regression analysis in an unstratified
population of 56 patients with SCLC.
Discussion
NSE-staining
The semiquantitative gradation allowed assessment of the
staining reaction. Establishment of a HSI on primary tumour
tissues enables comparison with the occurrence of NSE in
serum at presentation in both LD and ED.
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A high frequency of NSE has been demonstrated in SCLC
in tissues. In one study the frequency of NSE immunoreac-
tivity was only one in five (Dhillon et al., 1982). Later
investigations proved NSE-positivity in 58% of 31 investi-
gated tissues (Sheppard et al., 1984), while 70% of 99 in-
vestigated biopsies from primary tumour as well as from
metastases were NSE-immunoreactivity in a study by Bergh
et al. (1985). NSE was, however, found non-specific for
SCLC, as NSE was positive in 66% of non-SCLC tumours vs
88% of SCLC tumours (Hirsch et al., 1988) and in 33 vs
56% respectively (Lee et al., 1988). The concentrations of
NSE in 11 tissue homogenates of SCLC were 35 times higher
than in non malignant tissues and from four to nine times
that measured in non-SCLC (Fujita et al., 1987). Although
obtained using very small specimens, our results are in agree-
ment with those reported in previous studies. In our study,
82% of 56 primary tumours were NSE-positive. Our number
of traumatised specimens corresponds with that reported by
Bergh et al. (1985) from both primary tumours and meta-
stases. As NSE is a soluble enzyme, the traumatised tissues
might have achieved a higher gradation if not traumatised.
Both studies thus stress the importance of well preserved
tissues.
Serum-NSE and immunoreaction
Previous studies have been concerned with the presence of
the NSE in tumour tissue (Dhillon et al., 1985; Sheppard et
al., 1984; Carney et al., 1982; Fujita et al., 1987) and the
serum levels of NSE in SCLC (Tapia et al., 1981; Cooper et
al., 1985). The presence of a relative high concentration of
NSE in SCLC in both serum and tumour tissue are therefore
well documented.
The correspondence between serum level and tissue content
has not as far as we know been investigated. In our study
similar distributions of HSI scores were achieved in LD and
ED. The corresponding serum values were significantly
higher in ED compared to LD. Finally there was no relation-
ship between HSI score and serum levels of NSE. A HSI
index based on light microscopic findings in the most stained
area of the specimen is therefore not well correlated to serum
levels which presumably reflects the overall NSE release from
the tumour. Apparently, there exists no positive correlation
between serum concentration and tumour content of NSE.
Other techniques, such as flow cytometric analysis, may bet-
ter overcome this bias related to heterogeneity of the tumour.
Prognosis
Univariate analysis ofpretreatment prognostic factors includ-
ing HSI left serum NSE and extent of disease as the most
valuable factors. Multivariate analysis excluded HSI as a
prognostic factor. An investigation by Dhillon et al. (1985)
showed survival of four patients with NSE positive tumours
compared to four patients with a negative NSE reaction.
This is not in accordance with our results.
In conclusion, semiquantitative gradation of NSE in SCLC
specimens enabled us to establish a scoring index. A high
score was not associated with a high level of serum NSE.
Both univariate and multivariate analysis chose serum NSE
and PS as the most influential prognostic factors. Further-
more, as NSE is not specific for SCLC and heterogeneity of
tumour tissue is common, serum NSE level is preferable for
the estimation of prognosis.
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